Navigation Links
Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Puberty
Date:5/5/2008

raindicated in patients with hypersensitivity to GnRH or GnRH analogs.

About Central Precocious Puberty

Central precocious puberty (CPP) is the premature development of secondary sex characteristics that normally occur during puberty. In females, premature development is usually defined as earlier than 8 years of age, and in males, as earlier than 9 years of age. Children with CPP have an increased likelihood of psycho-social problems and also show significantly advanced bone age that can lessen their ability to attain full adult height.

About the Lawson Wilkins Pediatric Endocrine Society

The Lawson Wilkins Pediatric Endocrine Society promotes the acquisition and dissemination of knowledge of endocrine and metabolic disorders from conception through adolescence. The Society has nearly 1000 members representing the multiple disciplines of pediatric endocrinology. The members are dedicated to research and treatment of children with endocrine disorders; reproductive, bone, thyroid, diabetes, obesity, growth, pituitary and adrenal. The Society works to ensure the continuing education of its membership.

About Indevus

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA(R) and SANCTURA XR(TM) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromeg
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Dallas, Texas (PRWEB) , ... July 30, 2015 , ... ... professional and in-depth study on the current state of the global Propanol market with ... are Sinopec, CNPC, BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal ...
(Date:7/30/2015)... --  Senomyx , Inc. (NASDAQ: SNMX ), a ... develop, and commercialize novel flavor ingredients for the food, ... for the second quarter 2015. "Moving ... track to achieve our commercial and financial goals," stated ... Company. "Since our last quarterly earnings report, our two ...
(Date:7/30/2015)... 30, 2015  Discovery Laboratories, Inc. (Nasdaq: ... the second $1.0M tranche under a previously awarded ... valued at up to $3.0 million to support ... as a potential medical countermeasure to mitigate acute ... awarded an initial $1.0 million under this grant ...
(Date:7/29/2015)... 2015 Sanofi, un leader ... résultats pour le premier semestre 2015. Le Directeur ... Visionner l,interview vidéo et lire la ... Au sommaire de l,interview :  ... croissance - Diabète - ...
Breaking Biology Technology:Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... /PRNewswire/ - DNA Genotek, a leading provider of ... announced that The Anthony Nolan Trust, the UK,s largest ... a pilot project aimed at increasing donor recruitment. Bone ... HLA DNA testing to match leukemia patients with prospective ...
... ... leading technology services firm specializing in the intelligent integration of eCommerce, CRM and business ... to build an eCommerce system that will leverage its five divisions: Training, Field Services, ... ...
... CONVENTION, CHICAGO, Illinois , May 5, 2010 ... treatment for tuberculosis,(TB) will shortly start phase II clinical ... novel therapeutic vaccine called RUTI(R),in conjunction with an antibiotic. ... which reduces side effects and healthcare costs, by preventing,re-infection ...
Cached Biology Technology:DNA Genotek's Oragene(R) DNA Product Selected by The Anthony Nolan Trust for Pilot Project 2DNA Genotek's Oragene(R) DNA Product Selected by The Anthony Nolan Trust for Pilot Project 3DNA Genotek's Oragene(R) DNA Product Selected by The Anthony Nolan Trust for Pilot Project 4EDL Consulting Chosen to Implement Visionary Cloud-based eCommerce-Driven Learning Management System 2EDL Consulting Chosen to Implement Visionary Cloud-based eCommerce-Driven Learning Management System 3Archivel Farma's TB Vaccine May Cut Treatment Time From Nine Months to One 2Archivel Farma's TB Vaccine May Cut Treatment Time From Nine Months to One 3
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., a ... by the United States Patent and Trademark Office (USPTO) ... process leverages TAKE Solutions, Clinical Accelerators to reduce the ... (when compared to standardization without the accelerators), thus reducing ... At the heart of the patented ...
(Date:6/24/2015)... SAN JOSE, Calif. , June 24, 2015 ... leading developer of human interface solutions, today announced ... fingerprint sensor to provide secure authentication for its ... Having recently reached more than 200 million shipments ... shipment with Sharp reinforces Synaptics, strength, scalability and ...
(Date:6/23/2015)... June 23, 2015   MedNet Solutions , ... the entire spectrum of clinical research, is pleased ... ™ , the company,s intuitive, flexible and affordable ... Silver 2015 Stevie® Award by the American ... Services Website category.  The American Business Awards are ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2
... HOUSTON (Nov. 8, 2012) Four young scientists ... Research Institute (NSBRI). Through this two-year program, they conduct ... during long-duration spaceflights. In addition to receiving mentorship from ... are members of one of NSBRI,s seven research teams. ...
... in removing the extra copy of chromosome 21 in ... In Down syndrome, the body,s cells contain three ... A triplicate of any chromosome is a serious ... one-quarter of pregnancy loss from spontaneous miscarriages, according to ...
... 2012  Genomic Health, Inc. (Nasdaq: GHDX ) today ... Officer, Chairman and President will present at the following conferences ... on Thursday, November 15, 2012 at 2:00 p.m. Mountain Time ... Jaffray Healthcare Conference on Tuesday, November 27 at 2:30 p.m. ...
Cached Biology News:Space research institute awards postdoctoral fellowships to 4 scientists 2Extra chromosome 21 removed from Down syndrome cell line 2Extra chromosome 21 removed from Down syndrome cell line 3Genomic Health to Present at Two Upcoming Investor Conferences 2Genomic Health to Present at Two Upcoming Investor Conferences 3
Recombinant Human Erythropoietin (Tissue Culture Grade)...
One-step, microplate or cuvet, colorimetric, detection range 0.78 ug/dL to 65 ug/dL Zn in serum, plasma, urine, saliva etc. Procedure: 10 min....
Human PDGF R beta MAb (Clone # PR7212)...
Recombinant Mouse IL-23, CF...
Biology Products: